Logarithmic Corrections in Dynamic Isotropic Percolation

Based on the field theoretic formulation of the general epidemic process we study logarithmic corrections to scaling in dynamic isotropic percolation at the upper critical dimension d=6. Employing renormalization group methods we determine these corrections for some of the most interesting time dependent observables in dynamic percolation at the critical point up to and including the next to leading correction. For clusters emanating from a local seed at the origin we calculate the number of active sites, the survival probability as well as the radius of gyration.Comment: 9 pages, 3 figures, version to appear in Phys. Rev.

Statistical Mechanics of Nonuniform Magnetization Reversal

The magnetization reversal rate via thermal creation of soliton pairs in quasi-1D ferromagnetic systems is calculated. Such a model describes e.g. the time dependent coercivity of elongated particles as used in magnetic recording media. The energy barrier that has to be overcome by thermal fluctuations corresponds to a soliton-antisoliton pair whose size depends on the external field. In contrast to other models of first order phase transitions such as the phi^4 model, an analytical expression for this energy barrier is found for all values of the external field. The magnetization reversal rate is calculated using a functional Fokker-Planck description of the stochastic magnetization dynamics. Analytical results are obtained in the limits of small fields and fields close to the anisotropy field. In the former case the hard-axis anisotropy becomes effectively strong and the magnetization reversal rate is shown to reduce to the nucleation rate of soliton-antisoliton pairs in the overdamped double sine-Gordon model. The present theory therefore includes the nucleation rate of soliton-antisoliton pairs in the double sine-Gordon chain as a special case. These results demonstrate that for elongated particles, the experimentally observed coercivity is significantly lower than the value predicted by the standard theories of N\'eel and Brown.Comment: 21 pages RevTex 3.0 (twocolumn), 6 figures available on request, to appear in Phys Rev B, Dec (1994

Mean-field behavior for long- and finite range Ising model, percolation and self-avoiding walk

We consider self-avoiding walk, percolation and the Ising model with long and finite range. By means of the lace expansion we prove mean-field behavior for these models if $d>2(\alpha\wedge2)$ for self-avoiding walk and the Ising model, and $d>3(\alpha\wedge2)$ for percolation, where $d$ denotes the dimension and $\alpha$ the power-law decay exponent of the coupling function. We provide a simplified analysis of the lace expansion based on the trigonometric approach in Borgs et al. (2007)Comment: 43 pages, many figures. Version v2 with various (minor) changes (in particular in Sections 1.4 and A.1), and Sect. 4 is shortened. Journal of Statistical Physics (to appear

State of play and future direction with NOACs: An expert consensus.

Atrial fibrillation (AF) and venous thromboembolism (VTE) are cardiovascular conditions significant in contemporary practice. In both, the use of anticoagulation with vitamin K antagonists (VKAs) has been traditionally used to prevent adverse events. However, VKA therapy is associated with challenges relating to dose maintenance, the need to monitor anticoagulation, and bleeding risks. The non-vitamin K oral anticoagulants (NOACs) are becoming accepted as a clear alternative to VKA therapy for both AF and VTE management. The aim of this paper was to review contemporary evidence on the safety of NOACs in both conditions. A comprehensive literature review was conducted to explore key safety issues and expert consensus was achieved from eight professionals specialised in AF and VTE care. Consensus-based statements were formulated where available evidence was weak or contradictory. The expert statements in this paper form a key overview of the safety of NOACs compared with VKA therapy, and the comparative safety of different NOACs. It is apparent that a detailed patient work-up is required in order to identify and manage individual risk factors for bleeding and thrombosis prior to NOAC therapy. Additional measures, such as dose reductions, may also be used to maintain the safety of NOACs in practice

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362